Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanISleepinMS: cannabidiol for insomnia in multiple sclerosis
NL-OMON56335Phase 2Recruiting
- Sponsor
- Wageningen University & Research
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Insomnia and multiple sclerosis (MS), sponsored by Wageningen University & Research. Primary endpoint: Insomnia Severity Index score. Started Jul 2024; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Insomniamultiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON56335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56335.